Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions

CompletedOBSERVATIONAL
Enrollment

288

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
DyspepsiaHeartburnBile Reflux
Interventions
DEVICE

upper GIT endescopy

Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).

Trial Locations (1)

44511

Zagazig University Hospitals, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT05131802 - Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions | Biotech Hunter | Biotech Hunter